Merrion Pharma Cuts IPO Range

Merrion Pharmaceuticals Ltd., a Dublin, Ireland-based developer of oral-dosage forms of drugs with poor bioavailability, has cut its IPO price range from $10-$12 per share to $6-$7 per share. It still plans to offer four million American depository shares, and to trade on both the Nasdaq and IEX under ticker symbol MERR. Punk, Ziegel & Co. is serving as lead underwriter. Shareholders include Growcorp Ltd. and Elan Corp.